Reviewing Edesa Biotech Inc. (EDSA)’s and Galapagos NV (NASDAQ:GLPG)’s results

Both Edesa Biotech Inc. (NASDAQ:EDSA) and Galapagos NV (NASDAQ:GLPG) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Edesa Biotech Inc. 6 83749.89 N/A -1.16 0.00
Galapagos NV 133 0.00 N/A -1.69 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Edesa Biotech Inc. and Galapagos NV.


Table 2 has Edesa Biotech Inc. and Galapagos NV’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Edesa Biotech Inc. 0.00% -51.1% -48.4%
Galapagos NV 0.00% 0% 0%

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Edesa Biotech Inc. and Galapagos NV.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Edesa Biotech Inc. 0 0 0 0.00
Galapagos NV 0 0 5 3.00

Galapagos NV on the other hand boasts of a $172.6 average price target and a 7.10% potential upside.

Institutional and Insider Ownership

Edesa Biotech Inc. and Galapagos NV has shares held by institutional investors as follows: 25.9% and 16.78%. About 1.3% of Edesa Biotech Inc.’s share are held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Edesa Biotech Inc. -1.21% -31.65% -21.79% -37.91% -44.29% -10.62%
Galapagos NV -2.84% 32.93% 52.92% 71.36% 55.03% 89.01%

For the past year Edesa Biotech Inc. has -10.62% weaker performance while Galapagos NV has 89.01% stronger performance.


Galapagos NV beats on 5 of the 8 factors Edesa Biotech Inc.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.